Summit Therapeutics Inc. (SMMT) Form 8-K — Nov 4, 2026
$SMMTForm 8-KItems 2.02, 5.03, 5.07, 9.01Filed Nov 4, 2026, 4:51 PM ET0001599298-26-000088Original filing
Summit Therapeutics reported a Q3 2026 GAAP net loss of $208.4 million ($(0.26) per share), wider on a non-GAAP basis ($160.7M, $(0.20)) as ivonescimab clinical spending ramped, with cash and investments of $629.8 million at quarter-end plus the $2.0 billion AstraZeneca equity investment received post-quarter at an implied $18.36 per share. Shareholders overwhelmingly approved doubling authorized common shares from 1.0 billion to 2.0 billion (658.1M for vs 2.0M against), effective upon filing with Delaware on November 4, 2026.
Key figures
- Eps
- -0.26
- Total Assets
- 692900000
- Cash Position
- 629800000
- Shares Outstanding
- 798200000
- Pdufa date
- 2026-11-14
- Gaap rd q3 2026
- $169.1 million
- Gaap opex q3 2026
- $214.6 million
- Az conversion price
- $18.36
- Az equity investment
- $2.0 billion
- Nongaap opex q3 2026
- $166.9 million
- Atm gross proceeds q3
- $94.1 million
- Authorized shares new
- 2000000000
- Authorized shares old
- 1000000000
- Harmoni os hazard ratio
- 0.76
- Harmoni2 os hazard ratio
- 0.73
- Nongaap net loss q3 2026
- $160.7 million
- Harmoni gi1 os hazard ratio
- 0.75
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.